CYTODROX contains hydroxyurea, which has an antiproliferative effect. It affects DNA synthesis in cells, reducing their ability to divide and grow. This drug is used for treating chronic myelogenous leukemia and blood disorders such as sickle cell anemia. It may also be used as part of combination therapy for other cancers.
The product is used for:
Chronic myelogenous leukemia (CML)
Sickle cell anemia
Treatment of certain other cancers, including head and neck cancers
Treatment of other diseases requiring reduction of cell proliferation
CYTODROX is taken orally, typically 1 capsule (500 mg) 1-2 times a day, depending on the treatment regimen prescribed by the doctor. The dosage may be adjusted based on the patient's condition and response to treatment.
Contraindications:
Hypersensitivity to hydroxyurea or other components of the drug
Pregnancy and breastfeeding
Severe liver and kidney diseases
Active infectious diseases
Side Effects:
Nausea, vomiting
Gastrointestinal disturbances (diarrhea, constipation)
Allergic reactions (rash, itching)
Reduced white blood cell and platelet count
Fatigue, headache
